Cerebrospinal Fluid Galectin-1 Levels Discriminate Patients with Parkinsonism from Controls

Parkinson’s disease (PD) is the second most common neurodegenerative disorder in elderly people. Currently, the diagnosis of PD is based on neurological examination, neuroimaging, and the response to dopaminergic medication. The diagnosis can be challenging, especially at early disease stages, when...

Full description

Saved in:
Bibliographic Details
Published in:Molecular neurobiology 2019-07, Vol.56 (7), p.5067-5074
Main Authors: Marques, Tainá M., van Rumund, Anouke, Bruinsma, Ilona B., Wessels, Hans J. C. T., Gloerich, Jolein, Esselink, Rianne A. J., Bloem, Bastiaan R., Kuiperij, H. Bea, Verbeek, Marcel M.
Format: Article
Language:English
Subjects:
Aged
Basal ganglia
Biomarkers
Biomarkers - analysis
Biomarkers - cerebrospinal fluid
Biomedical and Life Sciences
Biomedicine
Brain diseases
Cell Biology
Central nervous system diseases
Cerebrospinal fluid
Cohort Studies
Diagnosis
Dopamine receptors
Enzyme-linked immunosorbent assay
Female
Galectin 1 - analysis
Galectin 1 - cerebrospinal fluid
Galectin-1
Geriatrics
Humans
Male
Mass spectrometry
Mass Spectrometry - methods
Mass spectroscopy
Middle Aged
Movement disorders
Neurobiology
Neurodegenerative diseases
Neuroimaging
Neurological diseases
Neurological disorders
Neurology
Neurosciences
Older people
Parkinson's disease
Parkinsonian Disorders - cerebrospinal fluid
Parkinsonian Disorders - diagnosis
Proteins
Tau protein
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Parkinson’s disease (PD) is the second most common neurodegenerative disorder in elderly people. Currently, the diagnosis of PD is based on neurological examination, neuroimaging, and the response to dopaminergic medication. The diagnosis can be challenging, especially at early disease stages, when the symptoms of patients with atypical parkinsonism (APD) may strongly overlap. Therefore, reliable biomarkers that are able to identify patients with PD are much needed. Here, we aimed to identify and validate new biomarkers for PD in cerebrospinal fluid (CSF). We performed a profiling experiment using mass spectrometry (MS) of CSF from ten PD patients and ten matched non-neurological controls. We selected one protein, galectin-1 (Gal-1), which was differentially expressed in PD vs. controls, and quantified its concentrations in CSF by enzyme-linked immunosorbent assay (ELISA) in three new cohorts of 37 PD patients, 21 APD patients, and 44 controls. CSF levels of Gal-1 were lower in PD in both the discovery and validation experiments and discriminated PD from controls with moderate–high accuracy levels (ELISA: area under the curve = 0.7). Similar levels of Gal-1 were found in PD and APD. Gal-1 levels were correlated to age in all groups and correlated in the PD patients to CSF levels of total tau, phosphorylated tau, neurofilament light chain (NFL), and the mini-mental state examination (MMSE) score. We conclude that MS profiling of proteins may be a useful tool to identify novel biomarkers of neurological diseases and that CSF Gal-1 levels may discriminate PD from non-neurological controls.
ISSN:0893-7648
1559-1182
DOI:10.1007/s12035-018-1426-9